We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Correspondence |

Apoptotic Responses to All-trans Retinoic Acid of Targretin-Resistant, Malignant, CD4+ Peripheral Blood T Cells From Patients With Sézary Syndrome

Sarah B. Newton, AB; Jessica S. Yoon, MD; Bernice M. Benoit, BS; Maria Wysocka, PhD; Alain H. Rook, MD
Arch Dermatol. 2007;143(5):659-675. doi:10.1001/archderm.143.5.661.
Text Size: A A A
Published online


Cutaneous T-cell lymphoma (CTCL) is a malignant, lymphoproliferative disease of CD4+ skin-trafficking T cells. Sézary syndrome (SS), the erythrodermic variant, is typically characterized by circulating malignant T cells. Bexarotene, a retinoid X receptor–specific retinoid, has been available for SS treatment since 2000. A subset of patients with SS treated with bexarotene do not respond clinically, which may correlate with the findings of Budgin et al1 that the malignant T cells from some patients with SS are resistant in vitro to the apoptotic effects of bexarotene.

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview


Place holder to copy figure label and caption

Flow cytometry dot plots from a representative patient. Cells were gated on CD4+/CD26 lymphocytes. Cy5-dUTP+ cells (above the line) are apoptotic. A, Medium at 96 hours; B, all-trans retinoic acid at 96 hours.

Graphic Jump Location




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

5 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles